Raymond James Financial Inc. assumed coverage on shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) in a report issued on Friday. The brokerage issued an outperform rating and a $16.00 price target on the stock.
Separately, Zacks Investment Research upgraded Adaptimmune Therapeutics PLC from a hold rating to a buy rating and set a $9.75 target price for the company in a research note on Tuesday, July 12th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Adaptimmune Therapeutics PLC currently has a consensus rating of Buy and a consensus price target of $15.95.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) opened at 6.92 on Friday. The company’s 50-day moving average price is $7.12 and its 200-day moving average price is $8.46. Adaptimmune Therapeutics PLC has a 52 week low of $6.19 and a 52 week high of $14.78. The company’s market capitalization is $489.83 million.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last issued its earnings results on Monday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.16. Adaptimmune Therapeutics PLC had a negative return on equity of 21.36% and a negative net margin of 427.33%. Equities analysts forecast that Adaptimmune Therapeutics PLC will post ($1.09) earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the company. Glenmede Trust Co. NA raised its position in shares of Adaptimmune Therapeutics PLC by 574.9% in the second quarter. Glenmede Trust Co. NA now owns 20,923 shares of the company’s stock worth $170,000 after buying an additional 17,823 shares during the period. Springbok Capital Management LLC purchased a new position in shares of Adaptimmune Therapeutics PLC during the first quarter worth about $202,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Adaptimmune Therapeutics PLC by 3.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 108,995 shares of the company’s stock worth $888,000 after buying an additional 3,519 shares during the period. Renaissance Technologies LLC raised its position in shares of Adaptimmune Therapeutics PLC by 286.3% in the first quarter. Renaissance Technologies LLC now owns 113,200 shares of the company’s stock worth $920,000 after buying an additional 83,900 shares during the period. Finally, New Leaf Venture Partners L.L.C. purchased a new position in shares of Adaptimmune Therapeutics PLC during the second quarter worth about $1,035,000. Institutional investors own 45.11% of the company’s stock.
Adaptimmune Therapeutics PLC Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.